Plan: OPEN | Option: Growth | Sailesh Raj Bhan

23 Jan 20 | 12:00 AM

156.55 -0.18 (-0.12%)

  • Outperforms

    2.98%

    Return (1Y)

    beaten S&P BSE Healthcare TRI by 1.93%

  • Less Volatile

    0.80%

    Standard Deviation (1Y)

    Lower Equity - Pharma by -0.30%

  • Not so consistent

    6/12

    Months

    Has beaten Equity - Pharma

  • Value research rating

    Not Rated

Stock Composition

NAV

Scheme Trivia

  • Reliance Pharma Fund (G) fund has been the 6th best in 5Y performance in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been given the 6th best Risk adjusted performance for the past 5Y in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been the 7th best in the 5Y SIP performance in the Equity - Pharma category

Critical Parameters

Everyone of us wants to create wealth by investing in top funds. Have a look at the key parameters that you need to check before deciding to invest in a mutual fund.

Returns

In last 1 year Nippon India Pharma Fund (G), has beaten by 1.93% (CAGR difference)

2.98%

Outperforms

This is Alpha

Performance Chart for Rs

Invested in

Risk

In last 1 year , the volatility of Nippon India Pharma Fund (G) is Lower than by -0.30%

0.80%

Less Volatile

Risk Meter

Peer Comparison on Risk - Return

Consistency

For 6 out of Last 12 Months, i.e 50% of the times It beaten its benchmark, Equity - Pharma

Consistency Meter

Outperforming Stocks Vs. Underperforming Stocks

Based on the last 1year analysis, currently there are, the benchmark the benchmark

View Stock Composition